Kura Oncology's stock price fell 18.5% because Johnson & Johnson released data related to a hematologic cancer treatment.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.